Population pharmacokinetics of the rilpivirine long-acting formulation after intramuscular dosing in healthy subjects and people living with HIV

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection

(2020) Chloe Orkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

(2020) Susan Swindells et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults

(2019) Scott L Letendre et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Long-acting injectable therapy

(2019) Ronald D’Amico et al.   Current Opinion in HIV and AIDS

Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine

(2018) Nadège Néant et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

(2017) David A Margolis et al.   LANCET

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals

(2016) Manel Aouri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers

(2015) R Verloes et al.   HIV MEDICINE

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial

(2015) David A Margolis et al.   LANCET INFECTIOUS DISEASES

Formulation and pharmacology of long-acting rilpivirine

(2015) Peter E. Williams et al.   Current Opinion in HIV and AIDS

Long-acting antiviral agents for HIV treatment

(2015) David A. Margolis et al.   Current Opinion in HIV and AIDS

A Compartmental Pharmacokinetic Evaluation of Long-Acting Rilpivirine in HIV-Negative Volunteers for Pre-Exposure Prophylaxis

(2014) A G A Jackson et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults

(2014) William Spreen et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Lack of Pharmacokinetic Interaction between Rilpivirine and Integrase Inhibitors Dolutegravir and GSK1265744

(2013) Susan L. Ford et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

(2013) Herta M. Crauwels et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Improving the Success Rate of Gluteal Intramuscular Injections

(2013) April E. Boyd et al.   PANCREAS

Beyond virological suppression: the role of adherence in the late HAART era

(2012) Adriana Ammassari et al.   ANTIVIRAL THERAPY

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE

(2010) HM Crauwels et al.   Journal of the International AIDS Society

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment

(2009) Lieven Baert et al.   EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS